Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider

The U.S. autoimmune disease therapeutics market is projected to rise from $32.18B in 2025 to $54.72B by 2035 (+$22.54B), while Europe is expected to grow from $24.32B to $41.66B (+$17.34B). Growth is attributed to increased biologics and biosimilars adoption, plus ongoing FDA/EMA approvals and precision medicine, supported by rising prevalence of conditions like RA and MS.

Analysis

This is more of a long-duration revenue-pool expansion than a clean near-term earnings catalyst. The best-positioned equities are the large-cap immunology franchises with durable physician habits, manufacturing scale, and enough indication breadth to amortize R&D: ABBV and JNJ in the U.S., and NVS/SNY on the Europe side. The less obvious winner is the biosimilar stack, because a bigger biologics market does not automatically mean better originator economics; it can just as easily mean faster share transfer to lower-cost alternatives and tighter payer control.

The market is likely underestimating how much of the growth gets diluted by rebate pressure, tendering, and step-therapy, especially in Europe. In other words, unit growth can be strong while net price/mix is mediocre, which favors companies with either patent-protected portfolios or scale in biosimilars rather than broad, mid-cap biotech exposure. The second-order beneficiary is sterile fill-finish/CDMO capacity, because chronic injectable demand raises utilization and makes manufacturing a strategic bottleneck.

Time horizon matters: the immediate tape reaction should be limited, but over 1-3 months the real catalysts are label expansions, payer formulary resets, and any readthrough from phase 3 immunology data. Over 6-18 months, the key risk is that biosimilar penetration and class-level safety scrutiny cap the profit upside even if the TAM keeps growing. The contrarian point: consensus will treat this as a bullish biotech growth story, but the cleaner expression is quality cash-flow concentration versus duration-heavy biotech optionality.

Key Decisions for Investors

• Long ABBV / short XBI for 3-6 months: best way to express chronic biologics monetization versus speculative biotech duration; target 1.5-2.0x upside-to-downside if immunology net sales re-accelerate while XBI stays multiple-sensitive.
• Add JNJ on weakness, 6-12 month horizon: immunology and inflammation exposure should be more resilient than the market gives credit for, but size it modestly because the upside is steadier margin defense than explosive growth.
• Overweight NVS versus broad European healthcare for a 6-12 month trade: Europe’s growth story should accrue disproportionately to scale players with biosimilar capability and distribution leverage, not pure originators.
• Use XLV as a defensive basket only if you want low-conviction exposure; otherwise avoid a broad long-biotech expression because the market-size data alone does not solve pricing and biosimilar dilution.
• Alert item, not a trade yet: if biosimilar tender prices or payer rebates compress faster than expected, fade any rally in originator-heavy names and rotate toward biosimilar-capable platforms.